Roche is a large pharma headquartered in Switzerland. Over the past three years, Roche has been involved in 61 licensing and acquisition transactions, with a primary focus on Small Molecules (14 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
10
Active Trials
50
Top Modality
Small Molecules
Focus Area
Oncology
Licensing, acquisition, and partnership transactions involving Roche in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| BTK degrader program | Nurix Therapeutics | Small Molecules | Unknown | collaboration | Jun 9, 2026 |
| Poseida cell-therapy platform | Poseida Therapeutics | Cell Therapy | Unknown | acquisition | May 24, 2026 |
| avapritinib | Blueprint Medicines | Small Molecules | Approved | co development | May 17, 2026 |
| PathAI digital pathology and AI diagnostic platform | PathAI | Other | Unknown | acquisition | May 17, 2026 |
| Digital pathology / AI diagnostics platform | PathAI | Other | Unknown | acquisition | May 7, 2026 |
| PRA023 (TL1A antibody) | Prometheus | Antibodies | Phase 2 | acquisition | May 1, 2026 |
| RVT-3101 / RO7790121 / afimkibart | Roivant | Antibodies | Phase 2 | license | May 1, 2026 |
| MORI-057 (integrin α4β7 inhibitor) | Morphic Therapeutic | Small Molecules | Phase 2 | license | Apr 29, 2026 |
| RVT-3101 (RO7790121) | Telavant | Antibodies | Phase 3 | acquisition | Apr 17, 2026 |
| protein degraders | C4T | Small Molecules | Unknown | collaboration | Apr 10, 2026 |
Showing 10 of 16 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where Roche is most active based on deal history and clinical trial data.
Key indicators of Roche's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Roche has 50 active clinical trials across 5 development phases.
7
Unknown
4
Not Applicable
9
Phase 1
17
Phase 2
13
Phase 3
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Roche is a large pharma company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 61 deals over the past three years, Roche ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Roche include Oncology (24 deals and trials), Solid Tumors (16 deals and trials), Metabolic (12 deals and trials), and Mega Deals (11 deals and trials). In terms of modality, Roche has shown particular interest in small molecules, antibodies, peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Roche and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Roche's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals